Overall, these data show that CD1d-Vδ2 bsTCE improves survival in multiple in vivo hematologic malignancy models using either expanded type 1 NKT and Vγ9Vδ2-T cells or PBMCs as effector cells and demonstrate antitumor efficacy with intermittent dosing. The gene discussed is CD1D; the disease is hematologic disorder.